1 July 2026
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held yesterday afternoon, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2) | 1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2025 together with the directors' reports and auditor's report on those accounts 1,457,300 96.22 5,966 0.39 1,514,592 22.27 16,829 | 2. To approve the Directors' Remuneration Report 1,307,710 93.00 47,125 3.35 1,406,161 20.68 125,260 | 3. To re-appoint PKF Littlejohn LLP as auditors 1,441,698 95.73 13,011 0.86 1,506,035 22.15 25,386 | 4. To authorise the Audit Committee to determine the level of the auditor's remuneration 1,349,329 95.78 8,150 0.58 1,408,805 20.72 122,616 | 5. To authorise the re-appointment of Vladislav Sandler 1,454,810 95.68 14,398 0.95 1,520,534 22.36 10,887 | 6. To authorise the re-appointment of Alexis Sandler 1,371,163 91.14 81,931 5.45 1,504,420 22.12 27,001 | 7. To authorise the re-appointment of Sir Marc Feldmann 1,454,149 95.66 14,591 0.96 1,520,066 22.35 11,355 | 8. To authorise the re-appointment of Peter Redmond 1,224,477 81.31 230,108 15.28 1,505,911 22.15 25,510 | 9. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act. 1,242,853 87.03 133,834 9.37 1,428,013 21.00 103,378 | Special Resolutions Votes for % of votes cast for Votes against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2) | 10. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act. 1,195,851 83.61 183,068 12.80 1,430,245 21.03 101,176 | 11. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting, 1,409,241 92.61 61,106 4.02 1,521,673 22.38 9,748 |
(1) The Company's issued share capital ("ISC") on 26 June 2026, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 6,799,961 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com | Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com | Peter Redmond, Director peter.redmond@hemogenyx.com | SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 | Matthew Johnson, Vadim Alexandre, Adam Cowl | AlbR Capital Limited Tel: +44 (0)20 7469 0930 | Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company LSE:HEMO headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGSDDFWSEMSEDM